LENZ Therapeutics, Inc.

Stage 4 · Declining · week 43

As of Oct 22, 2026, LENZ Therapeutics is in Stage 4, the downtrend phase, now in week 43 (since Dec 15, 2025). It closed at $3.25, 90.1% below its 52-week high and below its 200-day average, which is falling.

$3.25

+0.93% today

$102M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is LENZ early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 14w

S2 17w

S2 27w

S2 20w

S4 45w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 14w → S1 2w → S4 4w → S1 5w → S2 17w → S3 5w → S2 27w → S3 7w → S4 8w → S1 5w → S2 20w → S3 5w → S4 45w current

Total tracked: 165 weeks across 13 stage runs.

LENZ among Biotechnology510th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…510	LENZLENZ Therapeutics, Inc.	Stage 4 · wk 43	7	−13.6%

vs 52W High

-90.1%

$3.19 lo$32.70 hi

90.1% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 43

1w13w26w

Week 43, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-61.4%

200 DMA: $8.41 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.57x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-13.6%

-40.7%

-64.5%

YTD

-79.7%

-90.3%

Scan Membership

Breakout Watch

Latest: 2025-06-16

4 appearances in last 60 days. First seen: 2023-06-15.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 43 · Vol 0.57x

2026-10-21S4

Wk 43 · Vol 1.15x

2026-10-20S4

Wk 43 · Vol 1.09x

2026-10-19S4

Wk 43 · Vol 0.87x

2026-10-16S4

Wk 43 · Vol 1.27x

2026-10-15S4

Wk 42 · Vol 1.07x

2026-10-14S4

Wk 42 · Vol 1.40x

2026-10-13S4

Wk 42 · Vol 0.80x

2026-10-12S4

Wk 42 · Vol 0.80x

2026-10-09S4

Wk 42 · Vol 0.83x

2026-10-08S4

Wk 41 · Vol 1.39x

2026-10-07S4

Wk 41 · Vol 0.69x

Moving averages & range

50 DMA

$4.25

200 DMA

$8.41

52W High

$32.70

52W Low

$3.19

5D Low

$3.19

Resistance levels (recent highs)

20d High

$3.96

60d High

$5.96

120d High

$10.06

250d High

$31.97

Next resistance

+21.8%

to 20d High

ROE

-59.2%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.5

LENZ Therapeutics: quick answers

What stage is LENZ Therapeutics in?

As of Oct 22, 2026, LENZ Therapeutics (LENZ) is in Stage 4, the downtrend phase. It entered Stage 4 on Dec 15, 2025 and is in week 43. What the four stages mean

Is LENZ Therapeutics in an uptrend?

No. LENZ Therapeutics is in a Stage 4 downtrend. It trades 61.4% below its 200-day average, which is falling.

How far is LENZ Therapeutics from its 52-week high?

LENZ Therapeutics closed at $3.25 on Oct 22, 2026, 90.1% below its 52-week high of $32.70. Its 52-week low is $3.19.

How has LENZ Therapeutics performed over the past year?

As of Oct 22, 2026, LENZ Therapeutics is down 90.3% over the past year and down 79.7% so far in 2026.

Which sector and industry is LENZ Therapeutics in?

LENZ Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.